Recursion And Exscientia Announce Definitive Agreement To Combine Capabilities For Leading End-To-End Drug Discovery Platform
Portfolio Pulse from Benzinga Newsdesk
Recursion Pharmaceuticals (RXRX) and Exscientia (EXAI) have announced a definitive agreement to combine their capabilities to create a leading end-to-end drug discovery platform. The collaboration is expected to yield 10 clinical readouts in the next 18 months, $200 million in milestone payments over 24 months, and potentially $20 billion overall. The companies have $850 million in cash on hand and anticipate $100 million in annual synergies.
August 08, 2024 | 11:40 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Exscientia (EXAI) has entered into a definitive agreement with Recursion Pharmaceuticals to create a leading end-to-end drug discovery platform. The collaboration is expected to result in 10 clinical readouts in 18 months, $200 million in milestone payments over 24 months, and potentially $20 billion overall. The companies have $850 million in cash on hand and anticipate $100 million in annual synergies.
The partnership with Recursion is likely to enhance Exscientia's drug discovery capabilities, leading to significant clinical readouts and financial milestones. The anticipated synergies and cash on hand further strengthen the company's position.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Recursion Pharmaceuticals (RXRX) has entered into a definitive agreement with Exscientia to create a leading end-to-end drug discovery platform. The collaboration is expected to result in 10 clinical readouts in 18 months, $200 million in milestone payments over 24 months, and potentially $20 billion overall. The companies have $850 million in cash on hand and anticipate $100 million in annual synergies.
The partnership with Exscientia is likely to enhance Recursion's drug discovery capabilities, leading to significant clinical readouts and financial milestones. The anticipated synergies and cash on hand further strengthen the company's position.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100